Wuhan Anyou Zerui Tech Secures Tens of Millions RMB in Pre-A Funding to Advance Reproductive Health Smart Hardware

VCBeat (WeChat ID: vcbeat) has learned that Wuhan Anyou Zerui Technology Co., Ltd., a company focused on the reproductive health industry, recently completed a tens-of-millions-yuan Pre-A financing round, led by Gaonong Bio-Venture Capital. The funds raised in this round will be used for product research and development and the building of its operational team.

Wuhan Anyou Zerui Technology Co., Ltd. (hereinafter referred to as “Anyou Zerui”) is located in the National Reproductive Health Industry Base of Wuhan Optics Valley Biological City. It is a high-tech enterprise integrating Internet and smart hardware, specializing in the research, development, and operation of medical hardware products for reproductive health.

Currently, Anyou Zerui offers two product lines—hospital-based and home-based—along with dozens of intellectual property rights. The hospital-based product line features the Yunyou Smart Cloud Diagnostic Platform for Optimal Pregnancy Testing, a suite of dedicated laboratory instruments and system platforms designed exclusively for hospitals, providing standardized, intelligent, and professional solutions via a physician-facing mobile app. The home-based product line centers on the Yunyou Smart Quantitative Ovulation Detector, connecting users and physicians through a specialized preconception care app to deliver advanced fertility-tracking tools and professional guidance.

The World Health Organization predicts that infertility will be listed as one of the three major diseases affecting humanity in the 21st century, second only to cancer and cardiovascular and cerebrovascular diseases. In China, due to factors such as environmental degradation, increased work-related stress, and delayed childbearing age among women, the incidence of infertility has been rising year by year.

According to data from Ping An Securities Research Institute, the national incidence of infertility in China is approximately 12.5%–15%, meaning that about 12 to 15 out of every 100 women of childbearing age are affected by infertility, leading to a surge in demand for reproductive health services. In Europe and the United States, home testing has developed into a mature market, whereas in China, home testing for reproductive and maternal health remains in its early stages.

“Yunyou” is the proprietary brand under Anyou Zerui’s “pregnancy”-related product series. Positioned around the core mission of “advancing an era of optimal pregnancy, facilitating better conception, and promoting eugenics,” Yunyou advocates a cultural philosophy centered on “caring for women and encouraging women’s self-care.”

Within its product portfolio, the company leverages its platform’s science-based educational content to promote greater awareness of women’s health across society. Simultaneously, it provides physicians with standardized diagnostic tools and offers users at-home testing hardware. By connecting clinicians and households through an “Internet + smart hardware” solution, the company enhances professionalization, standardization, and healthcare efficiency, thereby enabling more women to receive scientifically grounded, systematic preconception guidance and medical services.

It is reported that the team behind Anyou Zerui Shi originates from well-known medical and internet companies such as Mindray and Baidu, with its core competitive advantage lying in its industry experience and capabilities in the research and development of medical products.

Mr. Liu Xiaobo, Founder and CEO of Anyouzerui, is an outstanding technological innovator at the Optics Valley Bio-City. He holds a bachelor’s degree in Biotechnology from Wuhan University, a master’s degree in Biophysics and Chemistry from the University of Guelph (Canada), and is a Ph.D. candidate in Bioengineering jointly supervised by Zhejiang University and the National Center for Nanoscience and Technology. He was selected into Wuhan’s third batch of the “3551” Talent Program. Previously, he was responsible for international markets, sales, and business module development for in-vitro diagnostics at Shenzhen Mindray, and served as Asia-Pacific Consultant for Medica Corporation (USA), overseeing business operations in the Asia-Pacific region.

Liu Xiaobo stated, “My years of experience managing Mindray’s international in vitro diagnostics (IVD) markets have given me a profound understanding of the global IVD industry. We are highly optimistic about the market’s growth potential and aim to leverage Yunyou’s precise, reliable, rapid, and user-friendly products to enable intelligent preconception care and health management. Our goal is to help individuals achieve healthier pregnancies and better birth outcomes, ultimately realizing our vision of an era of optimal prenatal care.”

Yu Zhenhua, Managing Director of Gaonong Bio-Ventures, stated, “We are delighted to invest in Anyou Zerui. The support from Anyou Zerui will help us expand our investments in technology and talent. As the reproductive health industry continues to evolve, we aim to assist practitioners and consumers by providing better products and services that support personalized diagnosis and treatment tailored to patients’ needs.”